Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells.  Although CDK4/6 inhibitors have shown promising results in the clinic, acquired resistance to these therapies is frequently observed. The successful development of next generation therapeutics necessitates a better understanding of the mechanisms underlying this …Read More >

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription factor an important drug target.  Activating point mutations in the ERα gene, especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies, and there is an urgent need to develop new strategies …Read More >

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types.  PKN3 mRNA is almost undetectable in normal adult tissues but is upregulated in various cancer cells, indicating that siRNA may be a promising approach to inhibit tumor growth by reducing the expression of PKN3.  WuXi AppTec scientists established different siPKN3 molecules and evaluated …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical …Read More >

NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer cells that help to suppress tumors, but also are involved in the generation and maintenance of adaptive immune responses.  The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of innate immune cells which provide antitumor …Read More >

Join WuXi AppTec at IMMUNOLOGY2024™. For this year’s annual meeting of the American Association of Immunologists (AAI), WuXi Biology has been selected to present five noteworthy posters, showcasing our panel of preclinical models representing urticaria, nephritis, rheumatoid arthritis, gout, and atopic dermatitis. Stop by Booth 777 to get your questions answered by one of our …Read More >

OncoWuXi Express| Immunology 2024™ Poster Sneak Peek Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the highlights of posters we will present at …Read More >

A new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum.  As the discovery pipeline widens and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver cell-killing radioisotopes. One area that is showing considerable promise is the incorporation of an isotope-chelating moiety …Read More >

Rat tumor models are a better mimic of human pathology compared to mice. The tumor stroma component of rats is about 1.5 to 2-fold higher relative to mice. Rats are considered an ideal model for preclinical efficacy studies, as they are physiologically, metabolically, and genetically more similar to humans.  To support drug discovery teams, WuXi …Read More >